Khloe Kardashian GLP-1: How a Regular Patient Would Actually Get Access

What Khloe Kardashian Has Actually Said

Khloe Kardashian has publicly and repeatedly denied using GLP-1 receptor agonists. In a 2023 conversation on the "Not Skinny But Not Fat" podcast, she attributed her body changes to a strict diet, consistent gym work, and what she described as finally finding a routine that clicked for her. She has not, to date, named any medication by brand or class.

Her sister Kim Kardashian similarly denied using Ozempic after visible weight loss, though other family-adjacent figures have acknowledged GLP-1 use in entertainment media. Inference from before-and-after photographs, the speed of visible transformation, and the near-elimination of facial fullness is just that: inference. This article labels it clearly as such.

The more clinically useful question is not what Khloe takes. The question is what a woman with similar goals, a similar life stage, and a similar body composition profile would need to qualify, access, and safely use a GLP-1 medication in 2025.

What GLP-1 Drugs Are and Why Women Search for Them

GLP-1 receptor agonists mimic glucagon-like peptide-1, an incretin hormone released from the gut after eating. They slow gastric emptying, reduce appetite signaling in the hypothalamus, and improve insulin secretion in a glucose-dependent way, meaning they do not cause hypoglycemia at therapeutic doses in non-diabetic users.

The FDA has approved two drugs specifically for chronic weight management in adults without diabetes:

• Semaglutide 2.4 mg weekly (Wegovy): approved June 2021
• Tirzepatide 2.5 to 15 mg weekly (Zepbound): approved November 2023

Both require a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease.

Why Women's Bodies Respond Differently

Female-specific pharmacokinetics matter here. Women generally carry a higher percentage of body fat, have lower lean mass relative to total weight, and experience hormonal fluctuations that directly affect appetite, insulin sensitivity, and fat distribution across the menstrual cycle and life stages.

Estrogen suppresses appetite partially through GLP-1 signaling pathways. When estrogen drops in perimenopause and menopause, women often experience a marked increase in hunger, a shift toward central adiposity, and a relative worsening of insulin resistance, even without meaningful changes in caloric intake. This is not a willpower problem. It is physiology.

In the STEP 1 trial, semaglutide 2.4 mg weekly produced a mean weight loss of 14.9% of body weight over 68 weeks in adults with obesity or overweight with comorbidities. Women made up approximately 75% of that trial population, which is rare for a metabolic drug trial, and is a meaningful data point for trusting its applicability to you.

Tirzepatide showed even larger effects. In SURMOUNT-1, the 15 mg dose produced a mean reduction of 22.5% of body weight at 72 weeks. Again, women represented the majority of participants.

GLP-1 Access by Life Stage: Where You Actually Are Matters

Your hormonal status changes what a clinician looks for, what dose may be appropriate, and what risks need monitoring. A single access pathway does not fit every woman.

Reproductive Years (Ages 18 to 40, Not Trying to Conceive)

This is the most straightforward access profile if your BMI meets threshold. A clinician will review your weight history, rule out secondary causes of weight gain (thyroid, PCOS, Cushing's), confirm you are not pregnant, and confirm you have reliable contraception if you are of childbearing potential.

GLP-1 drugs are Pregnancy Category X equivalent under current labeling. They are contraindicated in pregnancy. The semaglutide prescribing information specifically states that treatment should be discontinued at least two months before a planned pregnancy due to the drug's long half-life and potential fetal harm shown in animal studies. Tirzepatide labeling carries the same pregnancy warning.

You need to use reliable contraception throughout treatment. This means hormonal methods (pill, patch, ring, injection, implant, IUD with hormones) or a copper IUD, or consistent barrier use. "I'm usually careful" does not meet the clinical standard for a teratogenic drug.

Women With PCOS

PCOS affects 8 to 13% of women of reproductive age and is the most common endocrine disorder in women. Its core features include insulin resistance, androgen excess, and irregular ovulation, all of which are relevant to GLP-1 therapy.

GLP-1 drugs directly address insulin resistance, which is the metabolic driver in most PCOS phenotypes. A 2023 systematic review in Fertility and Sterility found that semaglutide and liraglutide both improved menstrual regularity and reduced androgen markers in women with PCOS, with effects beyond what weight loss alone would predict.

This matters for your access conversation. If your BMI is 26 and you have PCOS with documented insulin resistance, that comorbidity may qualify you for a GLP-1 prescription under the BMI 27-plus-comorbidity threshold. Bring your lab work: fasting insulin, HOMA-IR, testosterone, SHBG, and a recent A1C if you have one.

A critical safety note for PCOS: GLP-1 therapy can restore ovulation in previously anovulatory women. If you were relying on irregular cycles as de facto contraception, that assumption no longer holds once treatment begins. Unintended pregnancy on a teratogenic drug is a serious risk. Discuss contraception explicitly before starting.

Trying to Conceive

Stop the drug before you begin attempting conception. As noted above, semaglutide should be stopped at least two months before a planned pregnancy, and tirzepatide carries equivalent guidance. Neither drug has adequate human pregnancy safety data. Animal studies show fetal harm at doses extrapolated to human exposure ranges.

Some clinicians use GLP-1 drugs as a pre-conception metabolic intervention in women with obesity-related infertility or PCOS, with a planned discontinuation window before embryo transfer or active conception attempts. This is an off-label but clinically discussed strategy. ASRM's 2023 obesity and reproduction guidance acknowledges weight loss as an evidence-supported strategy for improving reproductive outcomes in women with BMI above 30.

Perimenopause (Typically Ages 40 to 55)

Perimenopause is arguably the life stage where GLP-1 access conversations are most underserved clinically. Estrogen fluctuation accelerates visceral fat accumulation. Women who have maintained a stable weight for years often find that weight begins shifting centrally in their mid-40s without obvious dietary changes.

The visceral fat that accumulates in perimenopause carries independent cardiometabolic risk beyond what BMI captures. A woman with a BMI of 28 and significant central adiposity, rising fasting glucose, and worsening lipid panels may have a stronger metabolic case for GLP-1 therapy than a woman with a BMI of 33 and otherwise normal labs.

The Menopause Society's 2023 position statement on menopause hormone therapy does not specifically address GLP-1 drugs, but the Society's clinical guidance on managing perimenopausal metabolic changes acknowledges insulin resistance as a central target. Some obesity medicine specialists now combine GLP-1 therapy with menopausal hormone therapy in perimenopausal women who meet criteria for both. Data on this combination is limited; what exists is observational.

Bring a complete metabolic panel, a lipid panel, and a DEXA scan result if you have one. Bone density monitoring becomes relevant in this life stage because rapid weight loss can accelerate bone mineral density loss, a concern that is amplified in perimenopausal women already experiencing estrogen-driven bone resorption.

Postmenopause

In postmenopausal women, the cardiometabolic risk justification for GLP-1 therapy is often clearer. The SELECT trial, published in The New England Journal of Medicine in November 2023, found that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease and overweight or obesity, without a diabetes diagnosis. Women were underrepresented at roughly 28% of that trial, which is a real limitation of applying this cardiovascular outcome data to postmenopausal women specifically. The evidence gap is worth naming: we are extrapolating, not directly citing female-specific cardiovascular trial data.

Pregnancy and Lactation Safety: The Full Picture

This section is required reading if you are pregnant, breastfeeding, or could become pregnant.

GLP-1 receptor agonists are contraindicated in pregnancy. This applies to semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), and dulaglutide (Trulicity).

The FDA labeling for semaglutide states that animal reproductive studies showed fetal harm at exposures below those seen in humans at the maximum recommended dose. Human data on pregnancy outcomes with GLP-1 use is limited to case series and pharmacovigilance reports, not controlled trials. The available case data does not establish safety.

For lactation: There are no adequate data on semaglutide or tirzepatide transfer into human breast milk. The molecular weight of semaglutide is approximately 4,114 daltons, which might limit transfer, but oral bioavailability in an infant is unknown. Until human lactation data exists, these drugs should not be used while breastfeeding. The prescribing information advises against use during lactation.

Contraception requirement summary:

| Life Stage | Contraception Requirement | |---|---| | Reproductive years, sexually active | Reliable method throughout; do not rely on cycle tracking | | PCOS (previously irregular cycles) | Mandatory, ovulation may restore | | Pre-conception planning | Stop drug 2+ months before attempting conception | | Pregnancy | Drug is contraindicated; stop immediately if pregnancy confirmed | | Breastfeeding | Drug should not be used |

If you become pregnant while taking a GLP-1 drug, stop the medication and contact your obstetric provider. Novo Nordisk and Eli Lilly each maintain pregnancy registries (1-800-727-6500 for Novo Nordisk; 1-800-545-5979 for Lilly) to collect outcome data.

Who This Is Right For, and Who It Is Not

The FDA threshold is a starting point, not a complete clinical decision.

Women Who May Be Good Candidates

• BMI of 30 or higher, regardless of comorbidities
• BMI of 27 or higher with PCOS, type 2 diabetes, hypertension, or obstructive sleep apnea
• Women with perimenopausal metabolic shift and worsening insulin resistance, even at lower BMI, if a clinician documents comorbidity
• Women who have tried structured lifestyle intervention for at least 12 weeks without adequate response

Women Who Are Not Candidates

• Currently pregnant or planning pregnancy within two to three months
• Breastfeeding
• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). GLP-1 drugs carry an FDA boxed warning for this risk based on animal data. The FDA label specifically contraindicates use in these populations.
• History of pancreatitis (use with caution; discuss with prescriber)
• Active eating disorder, particularly restrictive subtypes. GLP-1 drugs profoundly suppress appetite, and this effect is not benign in someone with anorexia history.

How the Access Process Actually Works for a Regular Patient

Telehealth has substantially reduced the access barrier. Here is the realistic sequence for a woman starting from zero.

Step 1: Confirm Your Starting Point

Pull your most recent weight and height to calculate BMI. If you do not have recent labs, most telehealth platforms will order them as part of the intake. Useful baseline labs include fasting glucose, A1C, fasting lipid panel, TSH, comprehensive metabolic panel, and, if you have PCOS history, free testosterone, SHBG, and fasting insulin.

Step 2: Choose a Prescribing Pathway

Three realistic options exist in 2025:

Primary care or OB-GYN: Your existing provider can prescribe GLP-1 drugs if they are comfortable with obesity medicine. Many are not, which is a real access barrier. If you are declined without clinical explanation, you can ask for a referral to an obesity medicine specialist.

Obesity medicine specialist: These physicians and NPs have the deepest prescribing experience. Wait times in major metro areas average four to six weeks for new patients. In rural areas, in-person access is often unavailable.

Telehealth: Platforms licensed in your state can conduct a synchronous (live video) intake, review labs, and issue a prescription often within 48 to 72 hours. Prescribing practices vary; some platforms use asynchronous questionnaires, which are adequate for follow-up but not ideal for an initial controlled substance evaluation. GLP-1 drugs are not controlled substances, but a live clinical conversation remains the standard of care for a new prescription.

Step 3: Understand the Insurance and Cost Reality

Wegovy and Zepbound have limited insurance coverage. GoodRx data as of mid-2025 shows list prices above $1,300 per month for both. Manufacturer savings programs (Novo Nordisk's Wegovy Savings Card, Lilly's Zepbound Savings Card) can reduce out-of-pocket costs to as low as $25 per month for eligible commercially insured patients. Medicare currently does not cover GLP-1 drugs for weight management, though this may change with pending legislation.

Compounded semaglutide has been widely available from 503B outsourcing facilities and 503A pharmacies during the FDA shortage period. As of early 2025, the FDA has signaled that the shortage designation for semaglutide is resolved, which affects the legal status of compounded versions. Discuss this with your prescriber.

Step 4: Titration and Monitoring

Starting doses are intentionally low to reduce nausea and GI side effects, which are the leading cause of early discontinuation. Standard titration for semaglutide begins at 0.25 mg weekly for four weeks, increasing stepwise to the maintenance dose of 2.4 mg over approximately 16 to 20 weeks. Tirzepatide starts at 2.5 mg weekly, with increases every four weeks.

A 2022 analysis in Obesity found that women reported nausea at slightly higher rates than men in GLP-1 trials, though the difference was modest. Eating smaller portions, avoiding high-fat meals, and dosing in the evening rather than morning may help.

Labs and weight should be reviewed at 12 weeks. If you have not lost at least 5% of body weight by 16 weeks at an adequate dose, current guidelines from the American Association of Clinical Endocrinology suggest reassessing whether the medication is appropriate for you.

The Evidence Gap: What We Do Not Know Yet

Women have been historically underrepresented in metabolic drug trials, and GLP-1 research is only beginning to correct that pattern. Several gaps remain.

Data on GLP-1 use in perimenopausal and postmenopausal women as a distinct population is almost entirely observational. No large RCT has enrolled specifically perimenopausal women and compared GLP-1 plus hormone therapy versus GLP-1 alone. The STEP trials did not stratify outcomes by menopausal status in the primary publications.

Data on GLP-1 drugs in women with a history of eating disorders is absent from major trials because those patients were excluded. This is a significant gap given that eating disorders disproportionately affect women and given the profound appetite-suppressive effects of these drugs.

Long-term bone density data in women taking GLP-1 drugs is limited. Rapid weight loss is associated with bone mineral density reduction, and this effect may compound perimenopausal bone loss. Baseline DEXA and monitoring during treatment is prudent in women over 45, though no formal guideline has yet formalized this as a standard recommendation.

When your clinician says "the evidence supports this for you," ask which population the evidence comes from. You deserve a specific answer.